EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Santen Pharmaceutical Co's enterprise value is $2,960 Mil.
Santen Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $416 Mil. Therefore, Santen Pharmaceutical Co's EV-to-EBITDA for today is 7.11.
The historical rank and industry rank for Santen Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
SNPHY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.25 Med: 12.95 Max: 30.53
Current: 7.11
During the past 13 years, the highest EV-to-EBITDA of Santen Pharmaceutical Co was 30.53. The lowest was 5.25. And the median was 12.95.
SNPHY's EV-to-EBITDA is ranked better than 77.37% of 707
companies
in the Drug Manufacturers industry
Industry Median: 13.81
vs SNPHY: 7.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Santen Pharmaceutical Co's stock price is $9.645.
Santen Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.525. Therefore, Santen Pharmaceutical Co's PE Ratio for today is 18.37.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Santen Pharmaceutical Co EV-to-EBITDA Historical Data
The historical data trend for Santen Pharmaceutical Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co EV-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's EV-to-EBITDA falls into.
Santen Pharmaceutical Co EV-to-EBITDA Calculation
Santen Pharmaceutical Co's EV-to-EBITDA for today is calculated as:
Santen Pharmaceutical Co's current Enterprise Value is $2,960 Mil.
Santen Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $416 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co (OTCPK:SNPHY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Santen Pharmaceutical Co's PE Ratio for today is calculated as:
Santen Pharmaceutical Co's share price for today is $9.645.
Santen Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.525.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Santen Pharmaceutical Co EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Santen Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.
Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNPHY has been successfully added to your 